Global Orthopedic Joint Reconstruction Market - 2024-2031

Overview

The global orthopedic joint reconstruction market reached US$ 20.20 billion in 2023 and is expected to reach US$ 36.56 billion by 2031, growing at a CAGR of 7.7 % during the forecast period 2024-2031.

Orthopedic joint reconstruction is a surgical procedure that aims to restore the structure and functionality of a joint damaged by injury, disease, or degeneration. The process typically involves removing the affected joint and replacing it with an artificial joint, known as a prosthesis, designed to mimic the natural movement and function of a healthy joint.

Orthopedic joint reconstruction includes various surgical techniques that repair or replace damaged joints to alleviate pain, restore mobility, and improve the quality of life for patients suffering from conditions such as osteoarthritis, rheumatoid arthritis, trauma, or congenital deformities. These factors have driven the global orthopedic joint reconstruction market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Orthopedic Disorders

The increasing prevalence of orthopedic disorders is significantly driving the growth of the global orthopedic joint reconstruction market and is expected to drive throughout the market forecast period.

The increasing prevalence of orthopedic conditions, including osteoarthritis, rheumatoid arthritis, and various musculoskeletal disorders, is a major factor driving global orthopedic joint reconstruction growth in the market. As the population ages, the incidence of these conditions rises, resulting in greater demand for joint reconstruction surgeries.

According to The Lancet Rheumatology research publication in November 2023, globally, there were approximately 494 million individuals affected by other musculoskeletal disorders in 2020. This represents a substantial increase of 123.4% from 221 million cases in 1990. Projections indicate that the number of cases will rise by 115% from 2020 to 2050, reaching an estimated 1,060 million prevalent cases by 2050. Most regions are expected to see at least a 50% increase in cases during this period.

The global age-standardized prevalence of these disorders was found to be 47.4% higher in females than in males, and the prevalence increased with age, peaking at ages 65 to 69 for both sexes. Musculoskeletal disorders ranked as the sixth leading cause of years lived with disability (YLDs) worldwide, accounting for approximately 42.7 million YLDs and were associated with about 83,100 deaths. All these factors demand the global orthopedic joint reconstruction market.

Furthermore, the increased number of orthopedic disorders needs innovative solutions in the orthopedic industry. For this key player in the industry, key initiatives and advanced product launches would propel this orthopedic joint reconstruction market growth. For instance, in November 2024, Johnson & Johnson MedTech introduced its new joint reconstruction solutions at the 2024 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting, highlighting the Solutions in Motion initiative. This initiative aims to integrate advanced surgical techniques, innovative implants, and data-driven enabling technologies to enhance joint reconstruction procedures.

The initiative represents a comprehensive strategy that combines various elements of orthopedic care, focusing on improving surgical precision and patient outcomes. By integrating advanced surgical methods with innovative implant designs and leveraging data analytics, Johnson & Johnson MedTech seeks to transform joint surgeries into more efficient and effective procedures.

Also, in October 2023, DePuy Synthes, a subsidiary of Johnson & Johnson MedTech, officially launched the VELYS Robotic-Assisted Solution in the European market, marking a significant advancement in orthopedic surgery technology. This innovative system is designed specifically for total knee arthroplasty (TKA) and aims to enhance surgical precision and patient outcomes. All these factors demand the global orthopedic joint reconstruction market.

Moreover, the rising demand for minimally invasive procedures contributes to the global orthopedic joint reconstruction market expansion.

High Costs of Implants

The high costs of implants will hinder the growth of the global orthopedic joint reconstruction market. These high expenses can discourage patients from undergoing essential surgeries, especially in developing nations where healthcare budgets are constrained. The financial strain caused by expensive implants may result in delays in treatment, negatively impacting patient outcomes and hindering overall orthopedic joint reconstruction market growth.

According to the Journal of Orthopaedic Business article news in July 2024, a study on PubMed yielded 469 articles related to "total knee arthroplasty implant cost," of which 14 provided new estimates for the cost of standard knee implants and the total expenses associated with primary total knee arthroplasty (TKA). The average cost of a standard knee implant was found to be $5,336 +- $1,671, while the mean total cost for primary TKA was $23,907 +- $9,514. Notably, the cost of the standard knee implant accounts for 22.3% of the overall expense for a primary TKA. Thus, the above factors could be limiting the global orthopedic joint reconstruction market's potential growth.

Segment Analysis

The global orthopedic joint reconstruction market is segmented based on product type, technique, procedure, end-user, and region.

Product Type:

The knee implants segment is expected to dominate the global orthopedic joint reconstruction market share

The knee implants segment holds a major portion of the global orthopedic joint reconstruction market share and is expected to continue to hold a significant portion of the global orthopedic joint reconstruction market share during the forecast period.

The knee implant segment within the global orthopedic joint reconstruction market is essential for meeting the growing demand for knee replacement surgeries. This segment includes various types of implants designed to replace damaged or diseased knee joints, primarily due to conditions like osteoarthritis, rheumatoid arthritis, and traumatic injuries.

According to the World Health Organization (WHO) data in July 2023, Osteoarthritis (OA) is a degenerative joint disease that affects the entire joint, including the surrounding tissues. It is most commonly found in the knees, hips, spine, and hands. With a global prevalence of 365 million, the knee is the most frequently affected joint, followed by the hip and hand. Among those with osteoarthritis, approximately 344 million individuals experience moderate to severe symptoms that could benefit from rehabilitation. The incidence of knee osteoarthritis is particularly high among older adults, with over 22% of individuals aged 40 and above globally affected by this condition. As the population ages, the demand for knee replacement surgeries is expected to rise significantly.

There is a growing trend toward minimally invasive surgical procedures that reduce recovery times and enhance patient outcomes. These techniques are becoming increasingly popular among both surgeons and patients, driving demand for knee implants that support such approaches. Innovations in implant materials and designs, including the use of 3D printing technology and patient-specific implants, are improving the effectiveness and longevity of knee replacements. These advancements are attracting more patients to consider surgical interventions. Thus, all these factors demand the orthopedic joint reconstruction market.

Furthermore, key players in the industry product launches and approvals would drive this segment's growth in the orthopedic joint reconstruction market. For instance, in February 2024, the Asian Orthopaedic Institute (AOI) at SIMS Hospital in Chennai launched a new ceramic knee replacement system, marking a significant advancement in joint replacement surgery. This introduction is part of the hospital's commitment to providing innovative orthopedic solutions and improving patient care. Ceramic knee implants offer several significant advantages over traditional metal implants, making them an increasingly popular choice for patients undergoing knee replacement surgery.

Also, in November 2024, Zimmer Biomet Holdings, Inc. received a Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement for its Oxford Cementless Partial Knee implant, marking a significant advancement in knee replacement technology. This approval is based on comprehensive safety and effectiveness data gathered from an Investigational Device Exemption (IDE) study and non-clinical testing specifically for cementless partial knee replacement (PKR). These factors have solidified the segment's position in the global orthopedic joint reconstruction market.

Geographical Analysis

North America is expected to hold a significant position in the global orthopedic joint reconstruction market share

North America holds a substantial position in the global orthopedic joint reconstruction market and is expected to hold most of the market share.

The incidence of orthopedic disorders, especially arthritis, is on the rise in North America. According to the Centers for Disease Control and Prevention (CDC), around 21.2% of U.S. adults (approximately 53.2 million people) were diagnosed with arthritis between 2019 and 2021. This significant prevalence is a major factor propelling the demand for joint reconstruction surgeries, as more individuals seek effective solutions to manage pain and regain mobility.

According to the American College of Rheumatology data in 2024, the U.S. performs a substantial number of joint replacement surgeries annually, with approximately 790,000 total knee replacements and 544,000 hip replacements conducted each year. This high volume reflects the ongoing need for effective orthopedic solutions and drives market growth.

The aging demographic in North America significantly contributes to market growth. As people age, they are more susceptible to joint-related issues, leading to an increased need for surgical interventions like total knee and hip replacements. As per Population Reference Bureau (PRB) data in January 2024, the number of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, the proportion of this age group within the total population is projected to rise from 17% to 23%.

Similarly, according to National Center for Biotechnology Information (NCBI) research data, by 2040, the number of U.S. adults with doctor-diagnosed arthritis is projected to increase by 49% to 78.4 million, representing 25.9% of all adults. Additionally, the number of adults experiencing arthritis-attributable activity limitation (AAAL) is expected to rise by 52% to 34.6 million, accounting for 11.4% of all adults.

Continuous advancements in medical technology have improved the effectiveness and safety of joint reconstruction surgeries. Innovations such as minimally invasive surgical techniques, robotic-assisted surgeries, and enhanced implant materials have made these procedures less invasive and more efficient, encouraging more patients to consider surgical options.

Furthermore, in this region, a major number of key players' presence, well-advanced healthcare infrastructure, government initiatives & regulatory support, investments, partnerships & collaborations, and product launches & approvals would propel the market growth.

For instance, in November 2024, Johnson & Johnson MedTech announced a strategic partnership with Responsive Arthroscopy, focusing on expanding its offerings in the sports soft tissue repair market. This collaboration involves an exclusive commercial distribution agreement in the United States, aimed at enhancing the range of advanced soft tissue repair solutions available for shoulder, foot, and ankle procedures.

Also, in October 2024, Smith+Nephew launched its Legion-hinged knee (HK) system featuring Oxinium implant technology in the U.S. market, representing a significant advancement in knee replacement solutions. This innovative system combines the benefits of metal durability, ceramic wear resistance, and superior corrosion resistance, aiming to improve patient outcomes and surgical efficiency. Thus, the above factors are consolidating the region's position as a dominant force in the global orthopedic joint reconstruction market.

Asia Pacific is growing at the fastest pace in the global orthopedic joint reconstruction market

Asia Pacific holds the fastest pace in the global orthopedic joint reconstruction market and is expected to hold most of the market share.

The prevalence of osteoporosis and arthritis is increasing across the Asia-Pacific region. According to the Asian Federation of Osteoporosis Societies (AFOS), hip fractures are projected to rise from 1.2 million in 2019 to 2.6 million by 2050. This growing incidence necessitates effective orthopedic interventions, including joint replacements.

Continuous innovations in orthopedic devices, such as minimally invasive surgical techniques and improved implant materials, are enhancing surgical outcomes and patient recovery times. Technologies like 3D printing, robotic-assisted surgery, and augmented reality are making surgical options more attractive to both patients and healthcare providers.

Many countries in the Asia-Pacific region are investing heavily in healthcare infrastructure, enhancing access to advanced medical treatments. This includes establishing specialized orthopedic centers equipped with the latest technology for joint reconstruction procedures. The increasing number of orthopedic surgeries performed annually in the Asia-Pacific region significantly contributes to market growth. As more patients seek surgical solutions for joint issues, the demand for advanced reconstruction devices continues to rise.

In Asia, particularly in countries like China and Japan, is rapidly increasing. This demographic shift is critical as older adults are more susceptible to joint-related disorders, leading to a higher demand for joint reconstruction surgeries.

Furthermore, key players in the region, product launches, and approvals would propel this global orthopedic joint reconstruction market growth. For instance, in April 2023, Prashanth Hospitals in New Delhi, launched a 4th Generation Robot specifically designed for joint reconstruction surgeries, marking a significant advancement in orthopedic technology. This innovative robot utilizes infrared cameras and optical trackers to create a precise 3D map of a patient's joint anatomy. This mapping capability allows for tailored implant selection and placement during surgical procedures, enhancing the overall accuracy of joint reconstruction.

Also, in January 2023, Aster Medcity launched a joint replacement robot following the successful completion of 2,500 joint replacement surgeries. This milestone reflects the hospital's commitment to advanced orthopedic care and the integration of robotic technology in surgical procedures in India.

The newly introduced robot is fully automated and designed for knee replacement surgeries. It enhances surgical precision by utilizing advanced imaging techniques, such as CT scans or MRIs, to create detailed 3D models of the patient's joint. This allows for personalized surgical planning tailored to each patient's unique anatomy. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global orthopedic joint reconstruction market.

Competitive Landscape

The major global players in the orthopedic joint reconstruction market include Johnson & Johnson (DePuy Synthes), Stryker, Smith + Nephew, Zimmer Biomet., Arthrex, Inc., Globus Medical, Enovis Corporation, Exactech, Inc., B. Braun SE, and MicroPort Scientific Corporation among others.

Key Developments

• In October 2024, Aradhana Orthopedic Hospital launched Shivamogga's first fully automated robotic joint replacement system, marking a significant advancement in orthopedic surgery within the region. This state-of-the-art technology aims to enhance the precision and effectiveness of joint replacement procedures, improving patient outcomes and recovery times.
• In July 2024, Orthofix Medical Inc. announced the 510(k) clearance and the first U.S. implantation of the Fitbone Transport and Lengthening System, a significant advancement in orthopedic technology designed to treat large bone defects in the femur and tibia. This innovative device is particularly useful for patients suffering from trauma, infections, or malignant conditions that result in substantial bone loss.
• In June 2024, Meril launched the MISSO ortho-robot, a fully indigenous surgical robot designed specifically for knee replacement surgeries. This innovative technology promises to significantly reduce the costs associated with these procedures, making them more accessible to a broader range of patients in India.

Why Purchase the Report?

• Pipeline & Innovations: Insights into clinical trials, product pipelines, and upcoming advancements.
• Market Positioning: Analysis of product performance and growth potential for optimized strategies.
• Real-World Evidence: Integration of patient feedback for enhanced product outcomes.
• Physician Preferences: Insights into healthcare provider behaviors and adoption strategies.
• Regulatory & Market Updates: Coverage of recent regulations, policies, and emerging technologies.
• Competitive Insights: Analysis of market share, competitor strategies, and new entrants.
• Pricing & Market Access: Review of pricing models, reimbursement trends, and access strategies.
• Market Expansion: Strategies for entering new markets and forming partnerships.
• Regional Opportunities: Identification of high-growth regions and investment prospects.
• Supply Chain Optimization: Assessment of risks and distribution strategies.
• Sustainability & Regulation: Focus on eco-friendly practices and regulatory changes.
• Post-Market Surveillance: Enhanced safety and access through post-market data.
• Value-Based Pricing: Insights into pharmacoeconomics and data-driven R&D decisions.

The global orthopedic joint reconstruction market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.